Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2025)

Gilead Sciences has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $400.0 million in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $400.0 million; the trailing twelve-month figure through Dec 2025 stood at $590.0 million (down 85.95% YoY), and the FY2025 full-year result was $590.0 million, down 85.95% from the prior year.
• Asset Writedowns and Impairment for Q4 2025 stood at $400.0 million, up from $190.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $2.7 billion in Q1 2022, with the low at $50.0 million in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $1.3 billion across 4 years, with a median of $1.1 billion in 2024.